{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004177","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.407034+00:00","generated_at":"2026-06-19T03:47:04.390614+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Director Karin Eastham to retire from Geron board; CEO and COO bonus targets raised","bullets":["Karin Eastham, Class III director, will retire effective May 31, 2023, after 13 years; not standing for re-election.","CEO John Scarlett's annual bonus target increased from 60% to 65% of base salary, effective Jan 1, 2023.","COO Andrew Grethlein's bonus target increased from 45% to 50% of base salary, effective Jan 1, 2023.","Eastham's departure is not due to any disagreement; she cited imetelstat's positive Phase 3 IMerge results."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004177","json":"https://secwatch.observer/filing/0000950170-23-004177.json","markdown":"https://secwatch.observer/filing/0000950170-23-004177.md","text":"https://secwatch.observer/filing/0000950170-23-004177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000095017023004177/0000950170-23-004177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000095017023004177/gern-20230221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:47:04.390614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c51daf54c6","claim":"Karin Eastham retired as Director at GERON CORP.","evidence_excerpt":"On February 22, 2023, Karin Eastham, a Class III member of the Company’s Board, notified the Board of her retirement from the Company’s Board after 13 years of service on the Company’s Board and imetelstat’s achievement of positive top-line results in the IMerge Phase 3 trial in lower risk myelodysplastic syndromes.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886744/000095017023004177/0000950170-23-004177-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}